Loading stock data…
MAIA
$1.34+0.01 (+0.75%)
Market ClosedLast close May 1
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MAIA Biotechnology, Inc. in the Healthcare sector is trading at $1.34. The stock is currently 58% below its 52-week high of $3.19, remaining 13.5% below its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why MAIA maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.34
Potential Upside
5%
Whystock Fair Value$1.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$12.13+805.6%
Range$10.27 – $14.00
Fundamentals
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-942.65%
Volume
Today's trading volume
577,441
Recent News
Cancer drug maker takes sudden pivot into crypto
A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of Directors has approved allocating up to 90% of ...
Maia’s NSCLC immunotherapy secures Phase II efficacy win
The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line NSCLC.
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
The study will assess ateganosine in individuals who have been heavily pre-treated in third-line (3L) NSCLC.
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roche’s checkpoint inhibitor atezolizumab, for the treatment of multiple hard-to-treat cancers. MAIA Chairman and CEO Vlad Vitoc stated that preclinical studies found ateganosine to be highly synergistic with atezolizumab. Published first on TheFly – the ultimate s
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial. The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc’s (NASDAQ:REGN) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months f